Stocks and Securities

The Italian drama continued on Tuesday, yet it may not have negatively weigh on investors, leaving the S&P 500 unchanged. The Dow Jones Industrial Average outperformed, climbing 0.5% to a new all-time high, while the Nasdaq Composite lagged for the second day in a row, closing 0.5% lower. The Russell 2000 continued to struggle on Tuesday, closing 1.0% lower, thus extending the weekly loss to -2.4%.

The weakness seen in the Russell 2000 can be attributed to the trade deal with US and Canada. This agreement improved the overall outlook for global trade and thus reducing demand for the smaller, domestically-focused companies.

Dow Industrial AverageS&P 500Nasdaq 100Russell 2000

 

 

 

 

 

 

 

 

 

 

 

The Dow’s success was attributed to the top-weighted Boeing (BA) closing up +1.1%, chipmaker Inte(INTC) closing +3.6%, and one of our picks Caterpillar (CAT) which closed up +1.7%.

FANG stocks continue to struggle on Tuesday. Facebook (FB) closed down -1.9%, now down 5.6% as of Friday due to increased concerns regarding security issues. Amazon (AMZN), and Netflix (NFLX) both fell -1.7% and -1.1%, respectively. Amazon (AMZN) shares dropped despite CEO Jeff Bezos stating that they will  be raising its minimum wage to $15 an hour for all U.S. employees, effective November 1.

Today, investors will receive the weekly MBA Mortgage Applications Index, September’s ADP Employment Change, and September’s ISM Services report.

Now let us turn into Teva Pharmaceutical (TEVA). We have covered Teva Pharmaceutical (TEVA) on multiple occasions;

TEVA PHARMACEUTICAL INC. (TEVA): Possibly the most undervalued global pharmaceutical company?

Teva Pharmaceuticals (TEVA): Bullish Narrative Continues, Our PT Stands

What do we think of the recent Teva Pharmaceuticals (TEVA) Sell-off?

The remaining of this post is for our members only.
REGISTER TODAY FOR ONE MONTH FREE TRIAL and BECOME A BETTER TRADER & Gain access to a list of BEST ETFs to buy today.
REGISTER TODAY

Further stocks research

Furthermore, we encourage our readers to look at our most recent article titled “New Frontiers in Genomic Medicine” as we highlighted Bluebird BioInc. (BLUE) as our next long-term investment opportunity.

Lastly, take time to read our latest piece “What are the best Cannabis Stocks to have in 2018?”.